Drug profile · INN
aclidinium
BRETARIS GENUAIR
aclidinium (BRETARIS GENUAIR) is a muscarinic acetylcholine receptor m3 antagonist. Associated with A.Menarini Australia Pty Limited.
EMA: approved TGA: approved Respiratory system (R03) R03AL05
Patents linked 1
Pipeline programs 2
News articles 0
Drug details — aclidinium
- Class
- Respiratory system (R03)
- Route
- —
- Patents
- 1
- Programs
- 2
- Data quality
- 0.83
Quick answer
aclidinium (BRETARIS GENUAIR) is a muscarinic acetylcholine receptor m3 antagonist. Associated with A.Menarini Australia Pty Limited.
Key facts
INN aclidinium
Brand BRETARIS GENUAIR
Mechanism Muscarinic acetylcholine receptor M3 antagonist
Therapeutic class Respiratory system (R03)
ATC code R03AL05
Originator A.Menarini Australia Pty Limited
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is aclidinium?
aclidinium (BRETARIS GENUAIR) is a muscarinic acetylcholine receptor m3 antagonist. Associated with A.Menarini Australia Pty Limited.
What is the brand name for aclidinium?
BRETARIS GENUAIR is a marketed brand name for aclidinium. Check FDA Drugs@FDA for the current US label holder and prescribing information.